Report updated May 5, 2026
Managing Dabigatran
For the app is designed for a broad range of clinicians, including general practitioners, cardiologists, haematologists, neurologists, anaesthetists, emergency specialists, and surgeons.
Overview · Full Intel report in progress
Managing Dabigatran is an established medical app that is completely free.
What is Managing Dabigatran?
Current Momentum
v4.0 · 117mo ago
ZombieLast updated 3528d ago. 5 versions tracked.
Competition
Rivals identification in progress
7-Day Rank Pulse 🇺🇸
MedicalNo ranking data
Rating Pulse 🇺🇸
Gathering signals...
What makes this app unique?
What Does It Look Like?
What Are The Key Features?
Provides correct dosing based on clinical indications and adjustments for renal impairment.
Offers safety advice for bleeding events, including information regarding the use of Idarucizumab.
Provides recommendations for treatment cessation prior to surgery and management protocols for emergency surgical procedures.
Assists clinicians in the interpretation of coagulation test results.
How much does it cost?
Who Built It?
HealthObs
Providing clinical decision support tools for healthcare professionals managing anticoagulant therapies. Focused on evidence-based dosing and emergency management protocols.
Portfolio
3
Apps
What other apps does HealthObs make?
Explore the full HealthObs report
Portfolio breakdown, audience, momentum, and every app published by HealthObs.
Analysis in progress, available soon
What do users think recently?
Analysis in progress, available soon
Analysis in progress, available soon
What is the competitive landscape for Managing Dabigatran?
How's The Medical Market?
How does it evolve in the Medical market?
Rank progression
1 active ranking tracked — 30-day window
Strategic analysis coming soon
SWOT, key takeaways & outlook
The outtake for Managing Dabigatran
Key Takeaways
This app serves as a specialized clinical reference tool for managing dabigatran therapy across various medical specialties.
Where Is It Heading?
Trend analysis
Available very soon